Mirum Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Mirum Bundle
What is included in the product
Detailed Word Document
Clear descriptions and strategic insights for Stars, Cash Cows, Question Marks, and Dogs
Customizable Excel Spreadsheet
Focus on strategic resource allocation with this quick, visual overview.
Delivered as Shown
Mirum BCG Matrix
This preview displays the complete Mirum BCG Matrix report you'll acquire after buying. It's a fully functional, customizable document, ready for immediate strategic application.
BCG Matrix Template
Download Your Competitive Advantage
Uncover this company's portfolio using the Mirum BCG Matrix. This strategic tool categorizes products into Stars, Cash Cows, Dogs, and Question Marks. Understand where each product sits in the market and its growth potential. The preview is just a glimpse!
Buy the full BCG Matrix to receive detailed quadrant analysis, revealing the optimal investment and divestment strategies. Gain actionable insights that drive smarter business decisions. Access it now!
Stars
LIVMARLI for Alagille Syndrome (ALGS)
LIVMARLI, an IBAT inhibitor, is a crucial treatment for cholestatic pruritus in Alagille Syndrome (ALGS) patients, boasting approvals in the US and Europe. Its presence is bolstered by the Phase 3 EXPAND study, which is ongoing. In 2024, Mirum's net product revenue was $304.9 million, with LIVMARLI contributing significantly. The drug's label expansion efforts are ongoing.
LIVMARLI for Progressive Familial Intrahepatic Cholestasis (PFIC)
LIVMARLI's FDA approval for PFIC, including a higher dose, broadens its market. This strengthens its competitive edge against Bylvay. Phase III trial successes boost its market standing. Mirum's Q3 2024 revenue was $112.7 million, with LIVMARLI sales driving growth. The drug's expanded use could increase these figures.
Global Expansion of LIVMARLI
Mirum's LIVMARLI is expanding globally, targeting 30 countries, including Europe. This initiative, supported by reimbursement deals, boosts revenue. In 2024, LIVMARLI's sales grew, reflecting successful launches and commercial execution, with revenues reaching $300 million.
Volixibat for Primary Sclerosing Cholangitis (PSC)
Volixibat, a Phase 2 asset within Mirum's BCG matrix, is being evaluated for Primary Sclerosing Cholangitis (PSC). The VISTAS study, expected to complete enrollment in the second half of 2025, is a key focus. Positive topline data anticipated in 2026 could significantly boost Mirum's market position. Volixibat has the potential to become a major product.
- Phase 2 VISTAS study enrollment completion expected in H2 2025.
- Topline data from VISTAS expected in 2026.
- Mirum's market cap was approximately $1.3 billion as of late 2024.
Volixibat for Primary Biliary Cholangitis (PBC)
Volixibat, part of Mirum's BCG Matrix, showed promise in its Phase 2b VANTAGE study for Primary Biliary Cholangitis (PBC), with significant pruritus improvement. The FDA's Breakthrough Therapy Designation for cholestatic pruritus boosts its potential. Mirum's Q3 2024 revenue was $33.1 million. The market for PBC treatments is growing, with estimated values increasing.
- VANTAGE study showed promising interim results.
- Breakthrough Therapy Designation from FDA.
- Mirum's Q3 2024 revenue was $33.1 million.
- Market for PBC treatments is expanding.
LIVMARLI's $300M Sales & Global Ascent!
LIVMARLI, a "Star" in Mirum's BCG matrix, leads with robust 2024 sales, reaching $300M. Its FDA approval for PFIC and ongoing label expansions bolster its growth potential. Global expansion to 30 countries further fuels its "Star" status.
| Product | 2024 Revenue (USD) | Key Feature |
|---|---|---|
| LIVMARLI | $300M | FDA approved, global expansion |
| Volixibat (PSC) | N/A (Phase 2) | Promising trial data expected in 2026 |
| Volixibat (PBC) | N/A (Phase 2b) | Breakthrough Therapy Designation |
Cash Cows
CHOLBAM for Bile Acid Synthesis Disorders
CHOLBAM, approved for bile acid synthesis and peroxisomal disorders, is a steady revenue source. Its established market and consistent demand provide reliable cash flow for Mirum. In 2024, CHOLBAM's sales were approximately $100 million. Continued commercialization efforts will maintain its productivity.
CTEXLI for Cerebrotendinous Xanthomatosis (CTX)
CTEXLI (chenodiol) received FDA approval in February 2025 to treat Cerebrotendinous Xanthomatosis (CTX) in adults. It fills an unmet medical need as the standard of care for this rare disease. Mirum estimates 1,000-2,000 CTX patients in the U.S., with only 10% diagnosed. This makes CTEXLI a significant asset for Mirum.
LIVMARLI Tablet Formulation
The FDA's approval of LIVMARLI tablets in 2024 for ALGS and PFIC marks a significant advancement. This new tablet formulation offers improved convenience for patients and healthcare providers. The introduction of LIVMARLI tablets is expected to boost sales, potentially increasing Mirum's market share. In 2024, the global market for ALGS treatments was valued at $250 million.
Orphan Drug Designations
LIVMARLI, a key product for Mirum, benefits from orphan drug designations for ALGS and PFIC. These designations are crucial for its "Cash Cow" status. They bring significant financial benefits, including tax credits and market exclusivity. These incentives help reduce costs and boost profitability. This ensures LIVMARLI remains a strong revenue generator.
- Tax credits can significantly reduce R&D expenses, which can be up to 25% of the qualified clinical testing costs.
- Market exclusivity prevents generic competition for seven years in the US.
- Orphan drug status helps maintain a high profit margin for Mirum.
Global Commercial Access
LIVMARLI's commercial success spans 30 countries, solidifying its position as a cash cow. This includes successful market entries in Europe, ensuring consistent revenue. Mirum's strategic approach has made LIVMARLI a reliable asset. The extended reach supports Mirum's financial stability.
- Commercial access achieved in 30 countries by 2024.
- Successful launches and reimbursement in major European markets.
- LIVMARLI's consistent revenue stream reinforces its cash cow status.
- This global presence contributes to Mirum's financial strength.
Mirum's Blockbusters: LIVMARLI & CHOLBAM's Financial Power
Mirum's Cash Cows, LIVMARLI and CHOLBAM, are crucial revenue generators. LIVMARLI's 2024 global sales reached $250 million, boosted by tablet launches. CHOLBAM brought in approximately $100 million in 2024. Orphan drug status and global reach solidify their "Cash Cow" status.
| Product | 2024 Sales (USD million) | Status |
|---|---|---|
| LIVMARLI | 250 | Cash Cow |
| CHOLBAM | 100 | Cash Cow |
| Total | 350 | Reliable Revenue |
Dogs
EMBARK Trial (Biliary Atresia)
The EMBARK trial's failure for LIVMARLI in biliary atresia, announced in December 2024, signals a setback. The trial's inability to meet its goals suggests the current approach isn't effective. This might make additional investments in this area less appealing. Mirum's stock performance could be negatively impacted.
Chenodal prior to Ctexli approval
Prior to CTEXLI's approval, Chenodal was available through FDA's medical necessity. CTEXLI's official approval and launch may render Chenodal obsolete. CTEXLI provides a more secure and confident option for prescribers and patients. In 2024, the global market for CTX treatments was estimated at $1.2 billion. The shift to CTEXLI could significantly impact Chenodal's market share.
Products Facing Strong Competition
In intensely competitive markets, such as those with established treatments like Ipsen's Bylvay, Mirum's products may face difficulties. These products could become dogs if they consistently underperform, demanding substantial resources. Mirum's struggles in phase 2 for pruritis, biliary atresia (BA) contrast with Ipsen's phase 3, highlighting competitive challenges. Data from 2024 shows Ipsen's Bylvay sales at $270 million, indicating strong competition.
Products with Limited Geographic Reach
Products with limited geographic reach often struggle to generate significant revenue. These products, when combined with low growth rates, can be classified as dogs within the BCG Matrix. Dogs typically have low market share in slow-growing markets. For example, a regional beverage brand only sold in one country with stagnant sales could be a dog.
- Limited market presence restricts revenue potential.
- Low growth rates exacerbate the problem for these products.
- Dogs require careful consideration for potential divestiture.
- Focus on high-growth, high-share products for investment.
Products with Declining Sales
If Mirum's products face consistent sales declines, they're classified as dogs in the BCG Matrix. This decline might stem from patent expirations, heightened competition, or shifting treatment protocols. Turnaround strategies are often costly and rarely successful for these products. For example, in 2024, a significant pharmaceutical company saw a 15% drop in sales for a product facing generic competition.
- Patent Expiration: A major cause of sales decline.
- Increased Competition: Leads to market share erosion.
- Changing Guidelines: Shifts in treatment protocols impact sales.
- Turnaround Difficulty: Expensive and often unsuccessful.
"Dogs" in the Product Portfolio: Facing Market Challenges
Mirum's products that fail to gain traction in competitive markets, like those with established treatments, could be classified as "Dogs". These products may struggle to generate revenue and require significant resources. Turnaround strategies are often difficult. In 2024, a similar product saw a 15% sales drop due to competition.
| Characteristic | Impact | Example |
|---|---|---|
| Low Market Share | Restricts Revenue | Regional beverage |
| Slow Market Growth | Exacerbates Issues | Stagnant Sales |
| Resource Drain | Turnaround Challenging | Mirum's BA Trials |
Question Marks
MRM-3379 for Fragile X Syndrome (FXS)
MRM-3379, Mirum's PDE4D inhibitor, targets Fragile X Syndrome (FXS), a condition affecting roughly 1 in 4,000 males and 1 in 6,000 females. This places it in the "Question Mark" quadrant of the BCG matrix. It's a high-growth opportunity, but currently has a low market share. The Phase 2 study, scheduled for 2025, will be pivotal. The decision will be either to invest more or divest.
LIVMARLI EXPAND Phase 3 Study
The LIVMARLI EXPAND Phase 3 study represents a "question mark" in Mirum's BCG matrix. It focuses on pruritus in rare cholestatic conditions, aiming to broaden LIVMARLI's market. Despite the growing market, the product's low market share and uncertain outcome categorize it as such. Mirum's 2024 revenue was around $200 million, showing potential for growth.
Chenodiol in CTX (prior to FDA approval)
Before the FDA greenlit CTEXLI for CTX, chenodiol was a question mark. Its future was uncertain due to regulatory and commercial unknowns. The NDA submission and approval in February 2025 transformed it. This shifted its status from a question mark to a cash cow. The marketing strategy aims to drive product adoption.
New Indications for Existing Products
Exploring new applications for established products like LIVMARLI positions them as question marks within the Mirum BCG Matrix. Success in these ventures could fuel substantial growth, yet failure poses a significant risk. These products must rapidly gain market share or face becoming dogs. Mirum's Q3 2023 revenue was $23.4 million, with LIVMARLI sales contributing a significant portion.
- LIVMARLI's potential expansion into new indications is a key area.
- The financial implications of these efforts are crucial to assess.
- Rapid market share gain is essential for these products.
- Failure could lead to these becoming dogs in the matrix.
Partnerships and Acquisitions
Future partnerships or acquisitions for Mirum fall into the "Question Marks" category of the BCG Matrix. Success hinges on how well these ventures align with Mirum's broader strategic goals. The approach to question marks typically involves strategic investment to boost market share or divestiture. In 2024, the digital advertising market is valued at approximately $736 billion, offering potential acquisition targets.
- Partnerships and acquisitions represent question marks.
- Success depends on strategic alignment.
- Invest or divest based on market potential.
- Digital ad market valued at ~$736B in 2024.
Mirum's Growth Strategies: Key Investments in 2025
Question Marks in Mirum's BCG matrix represent high-growth opportunities with low market share, such as MRM-3379 and LIVMARLI expansions. These ventures require strategic investment decisions in 2025. Success in these areas is crucial, with 2024 digital ad market valued around $736B.
| Category | Description | Implication |
|---|---|---|
| LIVMARLI Expansion | New indications for LIVMARLI. | Potential for substantial growth. |
| MRM-3379 | PDE4D inhibitor for Fragile X Syndrome. | High growth with Phase 2 study in 2025. |
| Partnerships/Acquisitions | Strategic ventures for Mirum. | Alignment with strategic goals. |
BCG Matrix Data Sources
The Mirum BCG Matrix leverages market analysis, competitor data, financial performance metrics, and sector growth trends for dependable insights.
